Sakakida, T., Masuishi, T., Onoe, T., Komine, K., Yonemori, K., Fujisawa, T., Tokumo, K., Harada, K., Hamauchi, S., Esaki, T., Hiroshima, Y., Watanabe, S., Takeda, H., Asayama, M., Hosoda, W., Taniguchi, H., Hayashi, H., Muro, K. (2026). Phase II basket trial of brigatinib for ALK fusion–positive solid tumors: ALLBREAK trial (WJOG15221M).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3105